(September 1, 2020, Hong Kong) Kintor Pharmaceutical Limited (stock code: 9939, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) signed a strategic cooperation framework agreement with Suzhou GloriousMed Biomedical Group Co., Ltd. (hereinafter referred to as “GloriousMed”) and HM Shuke (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as “HM Healthcare”), under which the three parties will create a patient-centered, integrated precise cancer treatment platform.

In line with the principle of "development of advantages, mutual promotion, long-term cooperation, mutual benefit and win-win", the three parties will promote the strategic cooperation, with the aim to create an integrated diagnosis and treatment platform and a patient-centered closed-loop marketing system, actively advance the integrated platform construction for companion diagnosis for patients of prostate cancer, breast cancer and other tumors, as well as big data analysis, patient management, new drug development and digital marketing.

GloriousMed is a leading supplier of integrated genetic detection solutions as well as a market leader in accurate detection of urological tumors in China. HM Healthcare, as a subsidiary of HM Healthcare Management Services, a joint venture between Mayo Clinic and Hillhouse Capital in China, focuses on providing one-stop empowered academic marketing solutions based on SaaS platform, and is committed to becoming a leading provider of digital medical marketing solutions in China. This cooperation started in the field of prostate cancer, and will extend to breast cancer and other multiple cancer fields, realizing common strategic extension of the three parties. The signing of the three-party framework cooperation agreement today lays the foundation for further cooperation among the three parties, and will build up energy for better services and care for patients.

CEOs of the three parties sign a strategic cooperation agreement

Kintor is confident with this cooperation and is full of expectation for the construction of the integrated platform. Dr. Youzhi TONG, founder, Chairman and Chief Executive Officer of Kintor Pharmaceutical, said, “we are glad to cooperate with professional and leading genetic detection companies like GloriousMed to create an integrated platform for the diagnosis and treatment of tumor patients and provide scientific support for the screening of potential effective population. Cooperating with Internet-based med-tech companies like HM Healthcare can integrate and link with peripheral resources and create an integrated caring and service platform. Offering better treatment and more care to patients is the responsibility and mission of Kintor Pharmaceutical.”

Ms. Jin Ge, Founder, CEO of GloriousMed, said: “The cooperation with Kintor Pharmaceutical, the leader of innovative drugs, is a new exploration and attempt of GloriousMed in business development and one of the strategic keys in future development. We hope to realize complementarity with innovative drug manufacturers and jointly develop integrated solutions for the diagnosis and treatment of prostatic cancer, breast cancer and other tumors to help patients realize accurate detection, optimize drug treatment protocols, monitor disease progression and evaluate the efficacy, in the meanwhile, to provide theoretic and clinical basis for the upgrade and iteration of tumor drugs.”

Ms. Zhang Xinyan, CEO of HM Health, said: “HM Healthcare is a subsidiary of HM Healthcare Management Services, the joint venture set up between Hillhouse Capital and Mayo Clinic in China. The strategic cooperation with Kintor and GloriousMed is one of the strategic directions of our company. By combining leading genetic detection and drug treatment means and with the help of Internet and big data technology, we hope to realize overall patient perception, assist doctors to educate patients of disease knowledge and make clinical management and finally realize the patient-centered big data management. We hope to make use of HM Healthcare’s powerful single disease computing model and algorithm techniques based on the industry-leading big data of gene detection and drug therapy at the clinical level as well as big data of Internet social media, in order to realize patient-centered big data analysis, insight and application management, offer intelligently assistance to doctors in clinical management for patients' diseases, precise education for patients' disease knowledge and clinical research-assisted single disease in-depth closed-loop application.